Dr. Grey AI

Exenatide (Byetta/Bydureon)

Peptide

Exenatide is a GLP-1 receptor agonist peptide approved by the FDA for type 2 diabetes, available as twice-daily (Byetta) and once-weekly extended-release (Bydureon) formulations. It is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from Gila monster saliva. The DURATION clinical trial program demonstrated efficacy for glycemic control and weight loss, while the EXSCEL trial assessed cardiovascular outcomes.

Quick Answer

What it is

Exenatide is a GLP-1 receptor agonist peptide approved by the FDA for type 2 diabetes, available as twice-daily (Byetta) and once-weekly extended-release (Bydureon) formulations. It is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from Gila monster saliva.

Key findings

  • Grade A: HbA1c Reduction (Type 2 Diabetes)
  • Grade A: Glycemic Control (HbA1c <7%) (Type 2 Diabetes)
  • Grade A: Body Weight Reduction (Type 2 Diabetes)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Exenatide (Byetta/Bydureon)

Quick Facts: Exenatide (Byetta/Bydureon)

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:18
  • Grade A Findings:5
  • Grade B Findings:7
  • Key Effect:Type 2 Diabetes
A5
B7
C4
D2
2 conditions · 18 outcomes

Detailed Outcomes

|
A
HbA1c Reduction
DURATION trials showed HbA1c reductions of 1.1-2.0%. DURATION-1 showed sustained 2.0% reduction at 52 weeks with once-weekly formulation.
large↓Improves
A
Glycemic Control (HbA1c <7%)
DURATION-1 showed 71% achieved HbA1c <7% and 54% achieved ≤6.5% at 52 weeks with exenatide once weekly.
large↑Worsens
A
Body Weight Reduction
DURATION trials showed mean weight loss of 2-4 kg over 6 months. DURATION-5 showed 5.1 lb weight loss with Bydureon vs 3.0 lb with Byetta.
moderate↓Improves
A
Fasting Plasma Glucose
DURATION trials showed significant reductions in fasting plasma glucose across all studies vs comparators.
large↓Improves
A
Systolic Blood Pressure
Long-term therapy showed sustained decrease in systolic blood pressure of approximately 2 mmHg over 3-6 years.
small↓Improves
B
Lipid Profile
DURATION trials showed improvements in fasting lipid profiles with exenatide therapy.
small↓Improves
B
Blood Glucose Control
46 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↓Improves
B
Neuroprotection
10 human trials support this finding. Human clinical trial data available.
moderate↑Improves
B
Liver Protection
8 human trials support this finding. Human clinical trial data available.
moderate↑Improves
B
Cognitive Function
5 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Safety/Tolerability
4 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
small↑Improves
C
Anti-Inflammatory Activity
4 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Cancer Cell Apoptosis
4 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
C
GI Protection
3 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Cardiac Protection
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Kidney Function
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
B
All-Cause Mortality
EXSCEL showed nominal 14% reduction in all-cause mortality (P=0.016), though this was not the primary endpoint.
moderate↓Improves

Research Citations (67)

Exenatide Is Neuroprotective in a New Rabbit Model of Hypoxia-Ischemia.
(2025)
PMID: 41227362
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial
(2024)
PMID: 39381950
Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial.
(2024)
PMID: 38565814
Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson's Disease Mice.
(2024)
PMID: 39430307
Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension.
(2024)
PMID: 38212401
Drug release profile of a novel exenatide long-term drug delivery system (OKV-119) administered to cats.
(2024)
PMID: 38762728
Exenatide administration time-dependently affects the hepatic circadian clock through glucagon-like peptide-1 receptors in the central nervous system.
(2024)
PMID: 39369911
Exenatide improves hypogonadism and attenuates inflammation in diabetic mice by modulating gut microbiota.
(2023)
PMID: 37210914
An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug.
(2023)
PMID: 36630826
Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial.
(2023)
PMID: 37883939

Related Peptides

Tirzepatide (Mounjaro/Zepbound)

Peptide

2 shared conditions · 17 outcomes

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). It is a 39-amino-acid synthetic peptide based on the native GIP sequence with a C20 fatty diacid modification enabling once-weekly dosing. The SURPASS and SURMOUNT clinical trial programs demonstrated unprecedented efficacy for glycemic control and weight loss, with up to 22.5% body weight reduction.

Semaglutide (Ozempic/Wegovy)

Peptide

2 shared conditions · 17 outcomes

Semaglutide is a GLP-1 receptor agonist peptide approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It is a 31-amino-acid peptide analog of human GLP-1 with 94% structural similarity but modified for extended half-life (approximately 1 week). The STEP, SUSTAIN, and SELECT clinical trial programs demonstrated consistent, substantial benefits for glycemic control, weight loss, and cardiovascular outcomes.